Dissolution tests for ER products

Dissolution Technologies

Volumn 5, Issue 4, 1998, Pages 5-11

  Sievert, Barbara ^a   Siewert, Martin ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG RELEASE; DRUG SOLUBILITY; EXTENDED RELEASE FORMULATION; FOOD DRUG INTERACTION; FOOD INTAKE; MEAN DISSOLUTION TIME; PH; QUALITY CONTROL; ROTATION; SIMULATION;

EID: 33644594819     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT050498P5     Document Type: Article

References (21)

1. J. G. Wagner and E. Nelson. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J. Pharm. Sci. 52 (6): 610-611 (1963).
2. G. Levy. Effect of dosage form on drug absorption - A frequent variable in clinical pharmacology. Arch. Int. Pharmacodyn. 152 (1-2) 59-68 (1964).
3. J. C. K. Loo and S. Riegelman. New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci. 57 (6) 918-928 (1968).
4. Dissolution, USP 18, 934-935 (1970).
5. Joint Report of the Section for Control Laboratories and the Section of Industrial Pharmacists of FIP: Guidelines for dissolution testing of solid oral products. Pharm. Ind. 43 334-343 (1981).
6. F. Langenbucher. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm. Ind. 44 (11) 1166-1172 (1982).
7. D. Brockmeier, D. Voegele and H. M. van Hattingberg. In vitro - in vivo correlation, a time scaling problem? Arzneimittelforschung/Drug Res. 33 598-601 (1983).
8. USP Subcommittee on Biopharmaceutics. In vitro / in vivo correlation for extended release oral dosage forms. Pharm. Forum 14 (4) 4160-4161 (1988)
9. A. Karim. Importance of assessing 'food effects' in evaluating controlled-release formulations. In: A. Yacobi and E. Halperin-Walega (eds). Oral sustained release formulations: Design and evaluations. Pergamon Press New York (1988)
10. V. E. Steinijans, R. Dietrich, H. Trautmann, R. Sauter and G. Benedikt. A novel approach to the specification of in vitro dissolution boundaries based on regulatory requirements for once-daily administration. Arzneimittelforschung/Drug Res. 38 1203-1209 (1988).
11. M. Nicklasson and F. Langenbucher. Description and evaluation of the flow cell dissolution apparatus as an alternative test method for drug release. Pharmacopeial Forum 16 (3) 532-540 (1990)
12. EEC Note for Guidance: Quality of prolonged release oral solid dosage forms, III/3172/91-EN (1991)
13. FDA Interim Guidance Immediate Release Solid Oral Dosage Forms - Pre- and Post- Approval Changes. (1994).
14. Bio-International Conference (1994)
15. <1088> ‘In vitro in vivo evaluation of dosage forms’, USP 23 (1995)
16. FIP Guidelines for Dissolution Testing of Solid Oral Products (1997).
17. Guidance for Industry SUPAC-MR: Modified-Release Solid Oral Dosage Forms Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (1997).
18. FDA Guidance for Industry Extended Release Solid Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations (1997)
19. European Pharmacopeia
20. USP 23 (1995)
21. P. U. Maturu, V. K. Prasad, W. N. Worsely, G. U. Shiu and J. P. Skelly. Influence of a high fat breakfast on the bioavailability of theophylline controlled release formulations: An in vitro demonstration of an in vivo observation. J. Pharm. Sci. 75 1205-1206 (1986).